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SYMPOSIUM TRANSCRIPTIONS
KEYNOTE ADDRESS
PREPARING THE GROUNDWORK FOR A
RESPONSIBLE DEBATE ON STEM CELL
RESEARCH AND HUMAN CLONING
0. CARTER SNEAD*
Many thanks to the New England Law Review for inviting me to
provide the keynote presentation for its annual symposium, "Stem Cell
Research and Human Cloning: Where Do We Draw the Line?" It is quite a
timely and important subject. Being a lawyer, it should not be surprising
that I will begin my remarks today with a caveat. My comments at this
event are entirely my own and are not intended to reflect the views of the
President's Council on Bioethics or any of its members.
The debate over both cloning and stem cell research has been intense
and polarizing. It played a significant role in the recently completed
presidential campaign, mentioned by both candidates on the stump, at both
parties' conventions, and was even taken up directly during one of the
presidential debates. The topic has been discussed and debated almost
continuously by the members of the legal, scientific, medical, and public
0. Carter Snead is General Counsel to the President's Council on Bioethics, a White
House advisory commission on the ethical and public policy questions arising from
advances in biomedical science and biotechnology. Mr. Snead is the principal drafter
of the April 2004 Council Report, Reproduction and Responsibility: The Regulation
of New Biotechnologies, which is a comprehensive critical assessment of the
governance (public and private) of activities at the intersection of assisted
reproduction, human genetics, and embryo research. Mr. Snead is an adjunct
Professor of Law at Catholic University of America. He received his J.D., magna cum
laude, from Georgetown University.
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policy commentariat. I believe that it is a heartening tribute to our national
polity that such a complex moral, ethical, and scientific issue has become a
central focus of our political discourse. But, as you have no doubt noticed,
the content of the discourse itself has been sometimes quite impoverished
and unsatisfying. No one camp in this debate is solely to blame for these
difficulties-partisans on all sides bear some measure of responsibility for
the current state of the public discourse. In the interests of improving the
quality of public deliberation and discussion on this matter, I will use the
balance of this keynote address to provide a few modest suggestions for
how the public debate might be improved. I will begin my remarks with a
few general observations applicable to both domains under consideration
today, stem cell research and cloning. Then I will focus on each separately;
first, directing my comments to stem cell research, and then turning to the
distinct (though obviously closely-related) matter of cloning.
The first step in moving towards a more responsible public debate on
both stem cell research and cloning is to define with clarity the overarching
subject under consideration, namely, the governance of science. In our
country, science is an enterprise that we hold in the highest esteem. But
science is not unbounded; it is subject to extensive regulation and
governance. These regulations are positive as well as negative-aiming to
promote scientific progress as well as to impose certain limitations in an
effort to avoid various types of harms. Thus, the central question for
policy-makers and the public in this context is what values and principles
should be brought to bear as we essay to govern ourselves in this area. It
would be helpful for discussants in the present debates to acknowledge and
affirm that these principles and values are identified and articulated through
the political process. This is as it should be. Public policy relating to
bioethics generally, and to stem cell research and cloning specifically, quite
properly present political questions that should be argued in political fora,
in political terms. They are first and foremost human questions about the
relationship between our strong desire to pursue scientific research with the
ultimate aim of alleviating human suffering, and our obligation to respect
moral and ethical boundaries. For this reason, I believe that the oft-repeated
criticism that "cloning and stem cell research should not be 'politicized,"'
without more, is not sound. To the contrary, the political domain is
precisely the proper place for this debate. But, of course, it is important to
stress that the political domain has rules, chief among them is that truth
should never be compromised in the service of advancing political
ideology. Of this, more later.
In short, I would submit to you that the current debate on both stem
cell research and human cloning would benefit greatly if all participants,
from the outset, approached these matters as they would any other issue of
great political import-by clearly defining which values they seek to
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promote and defend in this context (that is, clearly stating their argument),
and by responding directly to their opponents' account of the goods and
values at stake (that is, clearly responding to their opponents' argument on
its terms).
For this reason, discussants would do well to acknowledge the central
question in dispute, namely, what is owed to human embryos, and how
does this obligation stand in relation to other human goods such as the
alleviation of human suffering and the promotion of scientific freedom?
This is the moral, ethical, and legal question presented by human
embryonic stem cell research, in which the derivation of such stem cells
requires the disaggregation and thus destruction of living human embryos.
This is likewise the central question raised by one application of cloning-
so-called "therapeutic cloning," in which the process of somatic cell
nuclear transfer (SCNT) is used to create cloned human embryos, which
are then disaggregated for the purpose of deriving stem cell lines. By my
lights, the discussants in the public debate on this matter do not engage this
central question in all its richness. Too often, proponents of embryonic
stem cell research and therapeutic cloning fail to address directly the
question of the moral standing of embryos, and the necessary cost
associated with research that requires the destruction of embryonic human
life. Rather, they often try to short circuit the discussion either by ignoring
this crucial question, or by labeling the concern for the well-being of
human embryos as simply a "religious" view not requiring a response from
those who are not similarly religious. In point of fact, the most prominent
arguments for opposing research that requires the destruction of embryos
are not framed by reference to religious authority (though, for whatever
reason, these arguments seem to be embraced more readily by religious
people). The most prominent argument for maximal respect for embryonic
life is framed in secular terms-based on the biological and ontological
status of the human embryo itself. While there is certainly not time to fully
explore that argument here, it is rooted in the fact of the seamless
continuity of human development across biological stages-from zygote, to
embryo, to fetus, to newborn. More importantly, perhaps, the argument
turns on the absence of a meaningful point of developmental discontinuity
that might justify disparate treatment before or after that moment (i.e.,
before which instrumentalization and destruction for research is justifiable,
and after which the organism is entitled to maximal respect and protection).
This argument is developed in the Personal Statements of Professors
Robert George and Alfonso Gomez-Lobo in the President's Council on
Bioethics 2002 Report, "Human Cloning and Human Dignity: An Ethical
Inquiry."' Proponents of embryonic stem cell research and cloning for
1. See generally Robert George & Alfonso Gomez-Lobo, Statement of Professor George
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biomedical research would contribute to a more robust and responsible
debate if they would engage these arguments in a direct manner.
Similarly, those who would limit embryonic stem cell research and
cloning in the name of respect for embryonic human life could improve the
debate by forthrightly addressing the real-world ramifications of limiting
this avenue of scientific inquiry. Opponents of such research should
acknowledge that limitations on these practices might slow or even halt the
progress of science and delay indefinitely the development of cures for
injuries and dreaded diseases.
Finally, before moving on to a more specific discussion of the
subjects under consideration at this symposium, I would like to point to two
general principles (which I will elaborate on below) that should govern the
public debate on these matters. First, all sides should use fair, accurate, and
clear terminology. Moral arguments cannot and should not be won simply
through terminological manipulation or semantic games. Second, and last,
all sides in the debate have a duty to fully understand and fairly
characterize the present and proposed policies bearing on stem cell research
and cloning. This applies to their own policies, as well as the policies of
their political opponents. Of this, more later.
Turning specifically to stem cell research, I think it would behoove all
discussants in this particular debate to acknowledge at the outset that there
are different types of stem cell research, each carrying with it its own
promise and moral perils.
First, it is important to establish that stem cells come from different
sources--embryonic and non-embryonic. Obviously, stem cells derived
from non-embryonic sources, such as bone marrow, umbilical cord blood,
and so forth, do not raise the ethical concerns that arise from research that
requires the destruction of living human embryos. As such, it is crucial for
discussants to specify and clarify which type of stem cell research is under
consideration. It is exceedingly rare to find any individual in the public
debate that "opposes stem cell research." Invariably, the lines of dispute are
drawn according to the type of stem cells at issue.
Second, I think it is important for all parties to the stem cell debate to
understand and appreciate the historical nature of the debate thus far and
how it has unfolded over the past thirty years.
The debate over the government's role vis-d-vis research on in-vitro
embryos has been raging since the 1970s. There have been various
moments in the past thirty years where one branch of the federal
government has sought to support this research with federal dollars, while
(Joined by Dr. Gomez-Lobo), in PRESIDENT'S COUNCIL ON BIOETHICS, HUMAN
CLONING AND HUMAN DIGNITY: AN ETHICAL INQUIRY (July 2002), available at
http://www.bioethics.gov/reports/cloningreport/index.html.
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another branch resisted such a move. In fact, the positions of the federal
legislative and executive branches have switched at least twice in the past
thirty years on this particular question. For the past decade or so,
intentionally or unintentionally, the result of this stalemate has been a sort
of judicious silence on the part of the federal government, whereby the
research is not prohibited, but it is also not supported by federal funds.
It is within this trajectory of the debate that the current policy2 should
be located and understood. Understanding the historical context of the
present policy on the funding of embryonic stem cell research is the first
step in defending it or critiquing it.
The policy itself is actually quite subtle and complicated, and has not
been well described or understood by either its supporters or critics. The
policy is based on a fundamental, bright-line principle, namely, that
because embryos are human beings at the earliest stages of development,
they should not be instrumentalized or destroyed in service of the benefit of
others, even if those benefits are very great. Thus, the policy itself seeks to
advance the scientific research on stem cells to the maximal extent possible
without transgressing this bright line. Concretely, this means that federal
funding is authorized only for that species of stem cell research that does
not itself require, or otherwise create incentives for the destruction of
human embryonic life. In practice, this means that research on stem cells
derived from nonembryonic sources is subject to unlimited funding, as is
research on those embryonic stem cell lines derived before the
announcement of the policy (i.e., research where the embryo-destructive
act has already taken place). For the fiscal year 2003 the National Institutes
of Health (NIH) authorized $25 million for research involving these lines,
and allocated tens of millions of dollars for the development of research
infrastructure, training programs, and the like.
Thus, discussants in the stem cell research debate should not
characterize the present policy as a ban. It is a policy about federal funding.
Nothing is proscribed (evidenced by California's recent decision to fund
embryonic stem cell and cloning research to the tune of $3 billion,3 as well
as the efforts of Harvard's Doug Melton, who has created his own human
embryonic stem cell lines for use in research 4). Additionally, the present
policy should not be attacked or defended as a "compromise"-at least not
2. Address to the Nation on Stem Cell Research, 2 PUB. PAPERS 953 (Aug. 9, 2001),
available at http://www.whitehouse.gov/news/releases/2001/08/20010809-2.html.
3. Paul Elias, California's $3 Billion Stem Cell Proposition Passes, S.F. CHRON., Nov.
3, 2004, available at http://www.sfgate.com/cgi-bin/article.cgi?f=-/news/archive/2004/
11/03/politicsO459EST0073.dtl.
4. See William J. Cromie, Melton Derives New Stem Cell Lines, HARV. NEWS OFFICE,
Mar. 4, 2004, available at http://www.news.harvard.edu/gazette/2004/03.04/01-
stemcells.html.
2005]
NEW ENGLAND LAW REVIEW
in the conventional sense. It is a policy that is governed by a bright-line
principle. It is not a policy that is based on a utilitarian calculus that the
worth of human embryos outweighs the current promise of the research
using the approved lines. Thus, the policy should not be attacked or
defended by virtue of how much it promotes or impedes scientific progress.
It is a policy grounded in inviolable respect for the embryo, regardless of
the consequences to the research. And it should be critiqued or defended as
such.
On a related note, it is absolutely crucial for all parties to the debate
over stem cell research to be very judicious in describing the likely fruits of
the research in question. They should be careful not to overstate or
understate the promise of this avenue of research. Some proponents of
embryonic stem cell research have been guilty of inflating the promise of
this research, promising cures for every manner of disease or debilitating
injury. A recent example has been the oft-repeated invocation of former
President Ronald Reagan for the proposition that stem cell research holds
great promise for the treatment of Alzheimer's disease. According to the
nation's leading researchers in that particular field, this is not so.
Alzheimer's expert, Dr. Dennis Selkoe of Harvard (himself a vigorous
supporter of embryonic stem cell research) recently told the President's
Council on Bioethics that there was only a "very small possibility" that
stem cell research would be useful in treating the disease.5
By the same token, many opponents of embryonic stem cell research
are insistent that it holds no promise, and that only adult stem cell research
will prove efficacious in developing regenerative therapies. This too seems
to me to be an incomplete account, and is more of a speculative prediction
than a statement of certain fact.
I would counsel discussants on all sides of this debate to acknowledge
that we simply do not know which type of stem cell research is the most
promising. Embryonic stem cells are extraordinarily plastic and can, in
principle, become any tissue in the body. Therein lies their great virtue. But
it is also the case that this plasticity presents unique problems for directing
and controlling the development of such cells, with the formation of
teratomas (a type of tumor) presenting a significant concern. Adult stem
cells, it has been argued, are less plastic (although recent developments
have challenged this notion), but have proven useful in actual human
clinical trials-something that embryonic stem cell researchers have not yet
5. Session 2: Aging, Dementia and the Person: Clinical, Neurological and Existential
Perspectives on Alzheimer/Dementia: Meeting of the President's Council on
Bioethics (Jun. 24, 2004) (statements of Dennis J. Selkoe, Professor of Neurologic
Diseases, Harvard Medical School and Director of the Center for Neurologic
Diseases, Brigham and Women's Hospital, and David Shenk, author), available at
http://www.bioethics.gov/transcripts/june04/session2.html.
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accomplished. The future is unclear, and it is most accurate to say that both
avenues seem to promise a great deal. But, as I mentioned above, it is
important to always bear in mind that the promise of the research does not
in itself settle the moral question of what is owed to human embryos.
In addition to being intellectually honest about unknown facts, it is
equally important that parties to the stem cell debate be vigilant about
learning and describing known, demonstrable facts. A case in point-the
number of embryonic stem cell lines approved for federal funding.
Opponents and defenders of the current policy routinely misstate this easily
verifiable fact, claiming that there are only twelve lines, sixteen lines, or
twenty-two lines. In point of fact, there are seventy-eight embryonic stem
cell lines that are eligible for federal funding. However, before such lines
are available for research, the researcher must engage in a two-step
process: the line must be "characterized" (a scientific process) and the
relevant intellectual property agreements must be negotiated with the
owner of the line in question (a legal process). In the summer of 2002, only
one eligible line was available for research, while in the summer of 2003,
twelve were available. As of October 2004, twenty-two were available and
the number will presumably continue to grow. It also bears mentioning that
the number of stem cell lines is not the same as the number of stem cell
preparations that are shipped to scientists for research. In fact, over 500
preparations have been shipped to researchers so far, with 3,500 more
available for delivery.
I will now turn to the separate but obviously related matter of human
cloning. Cloning, that is the use of somatic cell nuclear transfer to produce
a cloned human embryo, is closely tied to embryonic stem cell research.
This is because one of its applications-cloning for biomedical research
(so-called "therapeutic cloning")-is aimed at the creation of embryos from
which stem cells can be derived for the sake of study and ultimately for the
development of therapies. However, it is also different in kind. Cloning is
not simply "a form of stem cell research," as it is sometimes described in
the media and by proponents of therapeutic cloning. Rather, it is a means of
producing the subjects of stem cell research, namely, human embryos. It
also marks a new innovation in mankind's ability to control the genetic
makeup of its progeny. There will be more on these matters later. Suffice it
to say, for present purposes, that discussants in the cloning debate would do
well to distinguish between cloning and stem cell research, while
recognizing the obviously deep connections between the two.
This leads me to revisit my earlier point regarding the importance of
using clear and precise terminology. To conflate "cloning" with "stem cell
research" more generally is confusing and if intentionally done,
intellectually dishonest. Such conflation can (and is perhaps intended to)
confuse supporters of conventional embryonic stem cell research into
2005]
NEW ENGLAND LAW REVIEW
believing that they should, as a logical matter, support therapeutic cloning.
But, as stated before, therapeutic cloning is distinct from conventional
embryonic stem cell research in important ways. President Clinton himself
recognized one of these crucial distinctions between creating embryos
solely for the sake of research and conducting research on embryos created
with a reproductive intent, but which are now destined for destruction (so-
called "spare" embryos). President Clinton rejected the 1994 NIH Human
Embryo Panel's recommendation to federally fund research in which
embryos are created solely for the sake of research on the grounds that this
pure instrumentalization of nascent human life was an ethical line that the
country was not ready to cross.
Proponents of therapeutic cloning would do a great service to the
public discourse on this matter by being very clear about what SCNT is and
what it does. In short, the product of somatic cell nuclear transfer is a
cloned human embryo. The purpose of therapeutic cloning is to create
embryos that will be disaggregated (and thus destroyed) for the sake of
acquiring their stem cells for research. However, in the public debate thus
far, advocates of this practice have sought to obscure this fact. Indeed, in
one of the bills introduced in the U.S. Senate, the product of SCNT was
referred to as an "unfertilized blastocyst." I defy you to find any
embryology textbook that uses this term. It simply does not exist. It is a
neologistic expression that communicates the notion that the product of
SCNT is not a human embryo, but something incomplete-a part and not
an integrated whole. By referring to the origin of the embryo, and by using
a less common term for embryo, the users of such terminology seek to
persuade the public that there is no moral issue. Nothing to see here. No
embryo. Move along. This is irresponsible in the extreme.
Just as it is crucial to use accurate terminology, it is likewise crucial
for the health of the public debate on cloning for discussants to fully
understand the policies that have been proposed at the national and state
levels. It would be useful for discussants to acknowledge that there are
currently no federal laws of any kind on the subject of cloning. Except for a
few oral pronouncements of the FDA (not since repeated or revisited),
there is no federal bar to cloning-either for producing children or for
biomedical research.
Being clear about the nature and substance of proposed legislation
means being clear about the impact of such laws, if enacted. It is therefore
necessary for the sake of intellectual honesty that the opponents of all
forms of cloning be clear that their proposals would limit the production of
particular embryos for stem cell research, and thus impede or even arrest
the scientific pursuit of regenerative therapies using embryonic stem cells.
Similarly, those proponents of legislation that would ban only cloning
for producing children, while permitting (or even encouraging) cloning for
486 [Vol. 39:479
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biomedical research, must be very clear about what this sort of law will
require. Not only would it sanction the creation of embryos solely for
research (which, as discussed above, raises novel ethical concerns), but also
it would in fact require, on pain of criminal penalty, that an entire class of
embryos (those produced by SCNT) be destroyed. Every bill that has been
proposed to ban cloning to produce children uses the same mechanism to
produce this result: they all make it a crime to transfer a cloned embryo
into a woman's uterus to initiate a pregnancy that will result in the birth of
a living child. What this means in practice is that all embryos created by
SCNT must be destroyed, as transfer to a woman's uterus for gestation is
the only possible means of preserving their lives. Proponents of these sorts
of laws should be forthright in acknowledging this innovation in the law. If
adopted at the federal level, it would move the United States from a
national policy that has never sponsored research requiring the destruction
of embryos to a national policy that requires, as a matter of law, that certain
embryos be destroyed.
I believe that the public debate over cloning could be improved by
further discussion and elaboration of the grounds for opposing cloning for
biomedical research, which are not rooted in respect for embryonic human
life. There are a number of public figures that are strongly in favor of
abortion rights, who vigorously support conventional human embryonic
stem cell research, but who nevertheless oppose cloning for biomedical
research. Some of these public figures may be addressing the symposium
today. They oppose this application of SCNT because they believe that it
opens the door for genetic modification more generally, and that may lead
to the perfection of the techniques of cloning for producing children. Many
feminists strongly object to SCNT because such experiments require a
massive number of human ova, which must be extracted from women via a
non-trivial and painful process. Such feminists (rightly in my view) worry
that this research presents a great potential for exploitation of women and
commodification of their body parts. This concern is particularly grave for
women in poverty, who might feel coerced to sell their ova. The debate
over cloning in Europe is in some ways richer than it is in the United States
because there is a critical mass of these voices in the public square. In the
United States these arguments are rarely heard and not well understood. As
a result, our public discourse on this subject is less complex and full than it
might be.
Finally, the public debate over cloning would be improved greatly by
a more robust discussion of the ethical arguments (pro and con) relating to
cloning to produce children. Currently, there is the appearance of
consensus on this question-most everyone opposes the practice for
reasons of safety. This may, however, prove to be an evanescent concern.
But there are other, richer ethical grounds to be debated and discussed on
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this matter. For example, there are concerns regarding identity and
individuality, the conversion of procreation into a process of manufacture,
the prospects of a new eugenics, and finally, the potential disruption of the
relations among the generations in families. These are all arguments against
cloning to produce children that are unrelated to safety. There are also
arguments in favor of cloning to produce children that have not been fully
explored and debated. There are possible arguments that this application of
SCNT might be a legitimate means to treat infertility, or to allow same-sex
couples to conceive biologically-related children. There are even arguments
that have not been fully aired in public about the possible virtues of trying
to reproduce a person of great value through the process of cloning. I am by
no means endorsing or supporting any of these aforementioned arguments,
but I raise them to illustrate the point that they have not been fully debated
and discussed publicly.
I thank you for your attention today, and I commend you in advance
for taking up these very important ethical questions in a serious fashion. I
hope that my remarks today will be useful as this symposium unfolds, and
that we can, working together, truly lay the groundwork for a responsible
debate on stem cell research and cloning.
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